Tilray (TLRY.US), a pharmaceutical and cannabis company, gained roughly 20% in pre-market trading as the firm announced it has entered into an agreement with Grow Pharma - the leader in supplying unlicensed cannabis medicines in the UK. Under the agreement, Grow Pharma will distribute Tilray’s medical cannabis products across the United Kingdom. Tilray’s stock price skyrocketed in recent weeks, which might be associated with hopes that Joe Biden could potentially introduce federal marijuana legalisation.
Tilray (TLRY.US) gained in recent weeks as Biden is expected to support medical cannabis legalisation. Stock price climbed above key area at $22.45 and is expected to open almost 20% higher today. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
